Paul D. Burgess

CIK 1744627 · See Remarks · last filed 2026-04-20

Paul D. Burgess is a corporate insider who has filed 10 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for KLRA, was dated Apr 20, 2026. Across all open-market trades the lifetime net is −$2.2M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

3

Total Filings

10

Lifetime Open-Market Net

-$2.23M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
KLRA	See Remarks	—	$16.74	—	$0	1	2026-04-20
Cerevel Therapeutics Holdings, Inc. (CERE) Delisted	See Remarks	45,727	$44.96	$2.06M	$501.8K	4	2024-01-23
Translate Bio, Inc. (TBIO) Delisted	Chief Operating Officer, CLO	0	$0.00	$0	-$2.73M	4	2021-09-14

Recent Filings

10 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-04-20	KLRA	Grant (A)	—	$0	EDGAR
2024-08-05	—	Disp (D)	−45,727	$0
2024-01-23	Cerevel Therapeutics Holdings, Inc. (CERE) Delisted	Grant (A)	—	$0	EDGAR
2023-12-21	Cerevel Therapeutics Holdings, Inc. (CERE) Delisted	Exer (M)	+23,847	$0	EDGAR
2023-08-07	Cerevel Therapeutics Holdings, Inc. (CERE) Delisted	Buy (P)	+21,880	$501.8K	EDGAR
2023-07-06	Cerevel Therapeutics Holdings, Inc. (CERE) Delisted	Grant (A)	—	$0	EDGAR
2021-09-14	Translate Bio, Inc. (TBIO) Delisted	Sell (S)	−71,833	-$2.73M	EDGAR
2021-03-09	Translate Bio, Inc. (TBIO) Delisted	Grant (A)	—	$0	EDGAR
2020-03-05	Translate Bio, Inc. (TBIO) Delisted	Grant (A)	—	$0	EDGAR
2019-03-12	Translate Bio, Inc. (TBIO) Delisted	Grant (A)	—	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.